[HTML][HTML] GLP-1 receptor agonists: beyond their pancreatic effects
X Zhao, M Wang, Z Wen, Z Lu, L Cui, C Fu… - Frontiers in …, 2021 - frontiersin.org
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …
[HTML][HTML] Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …
Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives
Astrocytes play key roles in the regulation of brain energy metabolism, which has a major
impact on brain functions, including memory, neuroprotection, resistance to oxidative stress …
impact on brain functions, including memory, neuroprotection, resistance to oxidative stress …
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review
N Reich, C Hölscher - Frontiers in neuroscience, 2022 - frontiersin.org
Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …
Hallmarks of brain aging: adaptive and pathological modification by metabolic states
During aging, the cellular milieu of the brain exhibits tell-tale signs of compromised
bioenergetics, impaired adaptive neuroplasticity and resilience, aberrant neuronal network …
bioenergetics, impaired adaptive neuroplasticity and resilience, aberrant neuronal network …
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: data from pooled double‐blind randomized controlled trials and nationwide …
Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like
peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for …
peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for …
Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities
Dysfunction of cell bioenergetics is a common feature of neurodegenerative diseases, the
most common of which is Alzheimer's disease (AD). Disrupted energy utilization implicates …
most common of which is Alzheimer's disease (AD). Disrupted energy utilization implicates …
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease
Although the brain has been considered an insulin-insensitive organ, recent reports on the
location of insulin and its receptors in the brain have introduced new ways of considering …
location of insulin and its receptors in the brain have introduced new ways of considering …
BDNF mediates adaptive brain and body responses to energetic challenges
Emerging findings suggest that brain-derived neurotrophic factor (BDNF) serves widespread
roles in regulating energy homeostasis by controlling patterns of feeding and physical …
roles in regulating energy homeostasis by controlling patterns of feeding and physical …
Insulin resistance and Parkinson's disease: a new target for disease modification?
There is growing evidence that patients with Type 2 diabetes have an increased risk of
develo** Parkinson's disease and share similar dysregulated pathways suggesting …
develo** Parkinson's disease and share similar dysregulated pathways suggesting …